OBI-833 is under clinical development by OBI Pharma and currently in the Phase I and Phase II in clinical pathway. The characteristics of the clinical trial as well as other attributes related to the drug, regulations, and company play a fundamental role in ensuring the likelihood of transition that the drug moves from its current development stage to next.

According to GlobalData, the latest event to affect OBI-833’s likelihood of approval (LoA) and phase transition for Gastric Cancer took place on 27 Apr 2021, which increased the likelihood that the drug progresses to the next phase in its clinical pathway and increased the likelihood of final approval for this indication.

In addition, the same event on 27 Apr 2021 increased OBI-833’s LoA and PTSR for Metastatic Breast Cancer, and increased LoA and PTSR for Metastatic Colorectal Cancer.

GlobalData uses proprietary data and analytics to provide a complete picture of this assessment in their OBI-833 Likelihood of Approval (LoA) and Phase Transition Success Rate (PTSR) Report.

OBI-833 overview

OBI-833 (Globo H-DT) is under development for the treatment of epithelial cancers like non-small cell lung cancer, pancreatic cancer, gastric cancer, colorectal cancer, breast cancers. The therapeutic candidate comprises of Globo H conjugated to the CT-CRM197, a non-toxic, mutated form of diphtheria toxin (DT). It acts by targeting globohexaosylceramide. The drug candidate is developed based on OPopS technology.

OBI Pharma overview

OBI Pharma is a biopharmaceutical company that develops therapies for the treatment of cancer and infectious diseases. The company’s pipeline products include adagloxad simolenin, an active immunotherapy which is intended for the treatment of metastatic breast cancer; and OBI-833, a cancer vaccine for epithelial cancers other than breast and ovarian cancer. It also develops active immunotherapies intended for the treatment of various lung, prostate, pancreatic, stomach and ovarian cancers. The company has collaboration with research institutes including cancer centers to enhance its pipeline products. It operates in the US, Taiwan, Hong Kong, Australia and China. OBI Pharma is headquartered in Taipei City, Taipei, Taiwan.

Quick View OBI-833 LOA Data

Report Segments
  • Innovator
Drug Name
  • OBI-833
Administration Pathway
Therapeutic Areas
  • Oncology
Key Developers
  • Sponsor Company: OBI Pharma
  • Originator: Academia Sinica
Highest Development Stage
  • Phase II

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.